MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, reported today that its proprietary iPSC Platelet technology is potentially capable of producing large-scale quantities of universal donor platelets for transfusion in almost any patient.
The research, which appears online (published-ahead-of- print) in Stem Cell Reports - the official journal of the International Society for Stem Cell Research (ISSCR) and published by Cell Press – by ACT scientists and their colleagues, shows that it is feasible to generate megakaryocytes and platelets from iPSCs in a scalable manner under feeder-free defined conditions. Universal platelets were generated by removing a gene essential to expression of the major histocompatibility (HLA) antigens, which are the main molecules responsible for cell and organ rejection. The platelets generated using this technology are functional and display features that were indistinguishable from those of human blood platelets.
Help employers find you! Check out all the jobs and post your resume.
